These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 29757894

  • 1. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
    Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU.
    Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894
    [Abstract] [Full Text] [Related]

  • 2. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
    Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S.
    J Clin Oncol; 2017 Feb 10; 35(5):536-543. PubMed ID: 27992268
    [Abstract] [Full Text] [Related]

  • 3. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, German PTLD Study Group, European PTLD Network.
    Lancet Oncol; 2012 Feb 10; 13(2):196-206. PubMed ID: 22173060
    [Abstract] [Full Text] [Related]

  • 4. End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry.
    Zimmermann H, Denecke T, Dreyling MH, Franzius C, Reinke P, Subklewe M, Amthauer H, Kneba M, Riess H, Trappe RU.
    Transplantation; 2018 May 10; 102(5):868-875. PubMed ID: 29189632
    [Abstract] [Full Text] [Related]

  • 5. Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
    Burns DM, Clesham K, Hodgson YA, Fredrick L, Haughton J, Lannon M, Hussein H, Shin JS, Hollows RJ, Robinson L, Byrne C, McNamara C, Vydianath B, Lennard AL, Fields P, Johnson R, Wright J, Fox CP, Cwynarski K, Chaganti S.
    Transplantation; 2020 Dec 10; 104(12):2582-2590. PubMed ID: 33104308
    [Abstract] [Full Text] [Related]

  • 6. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H, Reinke P, Neuhaus R, Lehmkuhl H, Oertel S, Atta J, Planker M, Gärtner B, Lenze D, Anagnostopoulos I, Riess H, Trappe RU.
    Cancer; 2012 Oct 01; 118(19):4715-24. PubMed ID: 22392525
    [Abstract] [Full Text] [Related]

  • 7. Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children.
    Giraldi E, Provenzi M, Conter V, Colledan M, Bolognini S, Foglia C, Sebastiani R, Fiocchi R, Gianatti A, DʼAntiga L, Rambaldi A.
    Transplantation; 2016 Feb 01; 100(2):437-45. PubMed ID: 26270449
    [Abstract] [Full Text] [Related]

  • 8. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dörken B, Oertel S.
    Transplantation; 2007 Apr 15; 83(7):912-8. PubMed ID: 17460562
    [Abstract] [Full Text] [Related]

  • 9. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
    Mumtaz K, Faisal N, Marquez M, Healey A, Lilly LB, Renner EL.
    Can J Gastroenterol Hepatol; 2015 Apr 15; 29(8):417-22. PubMed ID: 26076399
    [Abstract] [Full Text] [Related]

  • 10. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N, Büchler M, Foucher Y, Moreau A, Debiais C, Machet MC, Kessler M, Morelon E, Thierry A, Legendre C, Rivalan J, Kamar N, Dantal J.
    Transpl Int; 2014 Sep 15; 27(9):956-65. PubMed ID: 24964147
    [Abstract] [Full Text] [Related]

  • 11. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
    Sprangers B, Riella LV, Dierickx D.
    Am J Kidney Dis; 2021 Aug 15; 78(2):272-281. PubMed ID: 33774079
    [Abstract] [Full Text] [Related]

  • 12. DA-EPOCH-R for post-transplant lymphoproliferative disorders.
    DeStefano CB, Malkovska V, Rafei H, Shenoy A, Fitzpatrick K, Aggarwal A, Catlett JP.
    Eur J Haematol; 2017 Sep 15; 99(3):283-285. PubMed ID: 28509395
    [Abstract] [Full Text] [Related]

  • 13. Posttransplant lymphoproliferative disorder.
    Everly MJ, Bloom RD, Tsai DE, Trofe J.
    Ann Pharmacother; 2007 Nov 15; 41(11):1850-8. PubMed ID: 17940127
    [Abstract] [Full Text] [Related]

  • 14. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.
    Choquet S, Trappe R, Leblond V, Jäger U, Davi F, Oertel S.
    Haematologica; 2007 Feb 15; 92(2):273-4. PubMed ID: 17296588
    [Abstract] [Full Text] [Related]

  • 15. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S, Sekiguchi S, Kawagishi N, Akamatsu Y, Satoh K, Takeda I, Fukushima D, Kobayashi Y, Tokodai K, Fujimori K, Satomi S.
    Transplant Proc; 2011 Nov 15; 43(9):3299-301. PubMed ID: 22099782
    [Abstract] [Full Text] [Related]

  • 16. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
    Taylor E, Jones M, Hourigan MJ, Johnson DW, Gill DS, Isbel N, Hawley CM, Marlton P, Gandhi MK, Campbell SB, Mollee P.
    Nephrol Dial Transplant; 2015 Oct 15; 30(10):1774-9. PubMed ID: 26188340
    [Abstract] [Full Text] [Related]

  • 17. EBV and posttransplantation lymphoproliferative disease: what to do?
    Zimmermann H, Trappe RU.
    Hematology Am Soc Hematol Educ Program; 2013 Oct 15; 2013():95-102. PubMed ID: 24319169
    [Abstract] [Full Text] [Related]

  • 18. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases.
    Patel H, Vogl DT, Aqui N, Shaked A, Olthoff K, Markmann J, Reddy R, Stadtmauer EA, Schuster S, Tsai DE.
    Leuk Lymphoma; 2007 May 15; 48(5):885-91. PubMed ID: 17487731
    [Abstract] [Full Text] [Related]

  • 19. Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.
    Podoltsev N, Zhang B, Yao X, Bustillo I, Deng Y, Cooper DL.
    Clin Lymphoma Myeloma Leuk; 2013 Dec 15; 13(6):716-20. PubMed ID: 24035715
    [Abstract] [Full Text] [Related]

  • 20. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
    Zimmermann H, Nitsche M, Pott C, Reinke P, Babel N, Hermann RM, Hauser IA, Hahn D, Ritgen M, Pietschmann C, Klapper W, Anagnostopoulos I, Trappe RU, German PTLD Study Group and German Lymphoma Alliance.
    Ann Hematol; 2021 Aug 15; 100(8):2043-2050. PubMed ID: 33973053
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.